- Home
- TWN vs ITOS Comparison
TWN vs ITOS Comparison
Compare TWN & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- ITOS
- Stock Information
- Founded
- TWN 1986
- ITOS 2011
- Country
- TWN Hong Kong
- ITOS United States
- Employees
- TWN N/A
- ITOS N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWN Finance
- ITOS Health Care
- Exchange
- TWN Nasdaq
- ITOS Nasdaq
- Market Cap
- TWN 260.7M
- ITOS 280.6M
- IPO Year
- TWN N/A
- ITOS 2020
- Fundamental
- Price
- TWN $37.90
- ITOS $8.00
- Analyst Decision
- TWN
- ITOS Strong Buy
- Analyst Count
- TWN 0
- ITOS 3
- Target Price
- TWN N/A
- ITOS $21.33
- AVG Volume (30 Days)
- TWN 20.1K
- ITOS 470.7K
- Earning Date
- TWN 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- TWN 1.10%
- ITOS N/A
- EPS Growth
- TWN N/A
- ITOS N/A
- EPS
- TWN N/A
- ITOS N/A
- Revenue
- TWN N/A
- ITOS $35,000,000.00
- Revenue This Year
- TWN N/A
- ITOS $271.18
- Revenue Next Year
- TWN N/A
- ITOS N/A
- P/E Ratio
- TWN N/A
- ITOS N/A
- Revenue Growth
- TWN N/A
- ITOS N/A
- 52 Week Low
- TWN $25.22
- ITOS $7.09
- 52 Week High
- TWN $41.51
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- TWN 30.04
- ITOS 53.50
- Support Level
- TWN $37.81
- ITOS $7.63
- Resistance Level
- TWN $38.67
- ITOS $8.09
- Average True Range (ATR)
- TWN 0.78
- ITOS 0.30
- MACD
- TWN -0.21
- ITOS 0.06
- Stochastic Oscillator
- TWN 17.89
- ITOS 74.11
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.